1. Crawford ED, Abrahamsson PA . PSA-based screening for prostatecancer: how does it compare with other cancer screening tests? Eur Urol 54: 262-273, 2008 .
2. Heinlein CA, Chang C . Androgen receptor in prostatecancer. Endocr Rev 25: 276-308, 2004.
3. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostatecancer. Prostate 28: 251-265, 1996.
4. Velcheti V, Karnik S, Bardot SF, Prakash O . Pathogenesis
dissemination of cancerous cells. Moreover, it was shown that breast cancer patients with no expression of estrogen or progesterone receptors but positive for MMP-2 had worst disease-free and overall survival rates. [ 20 ] On the other hand, androgen as male steroid hormone can stimulate MMP-2 expression in human prostatecancer cells; [ 21 ] and elevated levels of androgen receptors, MMP-2 and MMP-9 in human hepatocellular carcinoma tissues are associated with higher invasive potential of these liver tumors. [ 22 ]
Therefore, based on the hypothesis proposed in the
mice. Diabetes 59, 1376–1385, 2010.
Herman W. The global burden of diabetes: An overview. In: Diabetes mellitus in developing countries and under-served communities (Ed. S. Dagogo-Jack), Springer International Publishing, Switzerland, pp. 1–5, 2017.
Holt SK, Karyadi DM, Kwon EM, Stanford JL, Nelson PS, Ostrander EA. Association of Megalin genetic polymorphisms with prostatecancer risk and prognosis. Clin Cancer Res 14, 3823–3831, 2008.
Hvidberg V, Jacobsen C, Strong RK, Cowland JB, Moestrup SK, Borregaard N. The endocytic receptor megalin binds the
Dmytro O. Minchenko, Daria O. Tsymbal, Olena O. Riabovol, Yuliia M. Viletska, Yuliia O. Lahanovska, Myroslava Y. Sliusar, Borys H. Bezrodnyi and Oleksandr H. Minchenko
and tumor growth. Oncotarget 5, 6670–6686, 2014.
Chevet E, Hetz C, Samali A. Endoplasmic reticulum stress-activated cell reprogramming in oncogenesis. Cancer Discov 5, 586–597, 2015.
Chua FY, Adams BD. Androgen receptor and miR-206 regulation in prostatecancer. Transcription 8, 313–327, 2017.
Cook N, Brais R, Qian W, Hak CC, Corrie PG. Endothelin-1 and endothelin B receptor expression in pancreatic adenocarcinoma. J Clin Pathol 68, 309–313, 2015.
Dashwood MR, Loesch A. Endothelin-1 as a neuropeptide: neurotransmitter or neurovascular effects
Olena O. Riabovol, Dariia O. Tsymbal, Dmytro O. Minchenko, Kateryna M. Lebid-Biletska, Myroslava Y. Sliusar, Olha V. Rudnytska and Oleksandr H. Minchenko
synchronized HeLa cells. Proc Natl Acad Sci USA 108, 21069–21074, 2011.
Dasgupta S, Putluri N, Long W, Zhang B, Wang J, Kaushik AK, Arnold JM, Bhowmik SK, Stashi E, Brennan CA, Rajapakshe K, Coarfa C, Mitsiades N, Ittmann MM, Chinnaiyan AM, Sreekumar A, O’Malley BW. Coactivator SRC-2-dependent metabolic reprogramming mediates prostatecancer survival and metastasis. J Clin Invest 125, 1174–1188, 2015.
de Guia RM, Herzig S. How do glucocorticoids regulate lipid metabolism? Adv Exp Med Biol 872, 127–144, 2015.
Dejeans N, Barroso K, Fernandez-Zapico ME, Samali
. Th erapeutic potential of curcumin in human prostatecancer. III.
Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostatecancer cells in vivo. Prostate 47, 293-303, 2001.
Eigner D, Scholz D. Ferula asa-foetida and Curcuma longa in traditional medical treatment and diet in Nepal. J Ethnopharmacol 67, 1-6, 1999.
Farombi EO, Abarikwu SO, Adedara IA, Oyeyemi MO. Curcumin and kolaviron ameliorate di‐n‐butylphthalate‐induced testicular damage in rats. Basic Clin Pharmacol Toxicol 100
? Transl Androl Urol 5(6):898-908,2016
5. Lopez DS, Advani S, Tsilidis KK, Wang R, Canfield S. Endogenous and exogenous testosterone and prostatecancer: decreased, increased or null-risk? Transl Androl Urol . 6(3): 566-579, 2017
6. Bjorntorp P . Endocrine abnormalities in obesity. Diabetes Rev 5: 52-68, 1997
7. Laaksonen DE, Niskanen L, Punnonen K et al . Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27(5):1036-1041, 2004
8. Kolovou GD, Anagnostopoulou KK, Salpea
Horaţiu-Cristian Popescu-Vâlceanu, Matei Bratu, Dan Matei Stancu, Maria Antonescu, Dianna Paula Tudor, Raluca Nan, Ramona Maria Drăguţ, Emilia Rusu, Mihaela Posea and Gabriela Radulian
://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx and http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
9. Rapp K, Schroeder J, Klenk J et al . Fasting blood glucose and cancer risk in a cohort of more than 140 000 adults in Austria. Diabetologia 49: 945–952, 2006.
10. Stattin P, Björ O, Ferrari P et al . Prospective study of hyperglycemia and cancer risk. Diabetes Care 30: 561–567, 2007.
11. Bonovas S, Filioussi K, Tsantes A . Diabetes mellitus and risk of prostatecancer: a meta-analysis. Diabetologia 47: 1071–1078, 2004.
12. Joost HG. Diabetes and cancer: epidemiology and
first-, second-, or third-line therapy and measured CTCs using an immunomagnetic separation technique.[ 9 ] They found that patients with unfavorable compared with favorable baseline CTCs had shorter median PFS (4.5 months vs . 7.9 months; P = 0.0002) and OS (9.4 months vs . 18.5 months; P < 0.0001), showing that the number of CTCs before and during the treatment is an independent predictor of PFS and OS in patients with mCRC.[ 9 ]
Application of CTCs in castration-resistant prostatecancer diagnosis
To establish the relationship between posttreatment CTC